- Both accelerated and standard H1-coil Deep TMS produced meaningful reductions in suicidality across SSI, HDRS, MADRS and CUDOS.
- Accelerated intermittent theta burst protocol showed non-inferiority for depression and a faster time to remission than once daily stimulation.
- Suicidality improved faster than overall depressive symptoms, especially with accelerated dosing, supporting scalable accelerated protocols for rapid symptom relief.
J Affect Disord. 2026 Aug 21:122409. doi: 10.1016/j.jad.2026.122409. Online ahead of print.
ABSTRACT
Suicide is the 10th leading cause of death in US adults. Standard once-daily repetitive transcranial magnetic stimulation (rTMS) can reduce suicidal ideation. Yet, antidepressant and anti-suicidal effects often take several weeks to emerge, while rapid improvement is often required. Accelerated TMS has been proposed as a strategy to hasten therapeutic response. A recent FDA-regulated multicenter trial evaluated accelerated intermittent theta burst Deep TMS with the H1-coil versus standard high-frequency Deep TMS in MDD. Both groups demonstrated high remission and response rates for depression, with the accelerated protocol showing non-inferiority and a shorter time to remission. The goal of this exploratory secondary analysis was to evaluate the impact of these two H-coil TMS dosing paradigms on suicidal ideation. The Scale for Suicide Ideation (SSI), as well as suicidality items of HDRS, MADRS and CUDOS were collected and analyzed. On all scales, both accelerated and standard Deep TMS protocols were associated with meaningful reductions in suicidality. The accelerated protocol achieved a faster onset of improvement. Comparison between the timeline of improvement in suicidality and in overall depressive symptoms found a trend for faster improvement in suicidality, especially with the accelerated protocol. These findings highlight the importance of treatment frequency in determining time to clinical benefit and support the use of scalable accelerated protocols for patients requiring more rapid symptom relief.
PMID:42628575 | DOI:10.1016/j.jad.2026.122409
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
Save as PDF
⭐ My Revision List

